Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03902821
Other study ID # ROAR
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 17, 2019
Est. completion date November 30, 2023

Study information

Verified date April 2024
Source Oregon Health and Science University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of the ROAR project is to evaluate an Oregon Department of Corrections (ODOC) pilot program that combines the use of extended-release naltrexone (XR-NTX) and Certified Recovery Mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and non-fatal opioid overdoses among female adults released from prison.


Description:

ROAR examines implementation of a novel overdose prevention strategy for justice-involved women as they re-enter community treatment settings after incarceration. The ODOC pilot project offers initiation of opioid antagonist treatment prior to release (extended-release naltrexone [XR-NTX]), ongoing support from a Certified Recovery Mentor (CRM), and facilitated entry into community treatment for substance use disorders. Community treatment may include continuation of XR-NTX,or transition to agonist therapy including buprenorphine or methadone, or no medication for opioid use disorder.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date November 30, 2023
Est. primary completion date July 14, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Be a woman (including transgender and non-binary adults assigned to women's housing at CCCF) - 18 years of age or older with a known release date during the 18-month recruitment period - Be released to Marion, Multnomah, Clackamas or Washington County, Oregon - Be willing and able to provide informed consent and HIPAA authorization for medical record abstraction and linkage to state administrative data - Meet DSM-V (Diagnostic and Statistical Manual) criteria for moderate or severe opioid use disorder - Be willing to establish ongoing care at the community SUD (substance use disorder) treatment site in county of release - Be willing to initiate XR-NTX prior to release from incarceration - Not be currently pregnant and must be willing to take at least one evidence-based measure to avoid becoming pregnant during treatment with XR-NTX Exclusion Criteria: A participant will be excluded if she - Has a severe medical, psychiatric, or substance use disorder that, in the opinion of the CCCF Qualified Mental Health Professional (QMHP)or study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study due to imminent risk of death - Has another medical condition leading XR-NTX to be contraindicated - Has chronic pain requiring ongoing pain management with opioid analgesics - Received methadone or buprenorphine maintenance therapy in the 4 weeks prior to consent - Has a planned surgery or other procedure within the next 4 weeks that will require opioid analgesia

Study Design


Related Conditions & MeSH terms


Intervention

Other:
XR-NTX and Certified Recovery Mentor
All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.

Locations

Country Name City State
United States Oregon Department of Corrections Wilsonville Oregon

Sponsors (6)

Lead Sponsor Collaborator
Oregon Health and Science University Bridgeway Recovery, CODA Inc., Health Insight, Oregon Department of Corrections, Oregon State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Any Opioid Overdose This is a binary outcome indicating a fatal or non-fatal opioid-related overdose event 6 months after release from incarceration
See also
  Status Clinical Trial Phase
Completed NCT04134767 - Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) N/A
Recruiting NCT05329142 - ASSIST: A Surveillance Study of Illicit Substance Toxicity